Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study - Wikidata - wikimedia - TriplyDB

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study

http://www.wikidata.org/entity/Q24633579

about

Pharmacogenetics as a tool to tailor antiretroviral therapy: A review Individualization of antiretroviral therapy--pharmacogenomic aspect Insights into CYP2B6-mediated drug-drug interactions Comparable long-term efficacy of Lopinavir/Ritonavir and similar drug-resistance profiles in different HIV-1 subtypes Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection Single Nucleotide Polymorphisms in Cellular Drug Transporters Are Associated with Intolerance to Antiretroviral Therapy in Brazilian HIV-1 Positive Individuals Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti.Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.Factors associated with remaining on initial randomized efavirenz-containing regimens.ABCB1 variation and treatment response in AIDS patients: initial results of the Henan cohort Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review.Pharmacogenomics of antimicrobial agents.Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing.Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial)Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults.Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases.Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis.Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.Global HIV/AIDS Clinical and Translational Pharmacology A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.Individualization of antiretroviral therapy.Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study.Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance

P2860

Q26797938-CADE1E77-734C-42DA-850C-28B385DC2C1C Q28070574-9244E9B6-E9C4-443E-8434-83C9DA43D3B5 Q28078857-E874D4FD-1A3B-469F-A656-7F84D89DD10D Q28539169-04715429-9397-426A-9073-B5B9684FE5D4 Q28548638-7C741DA2-700C-4D3C-ACD9-D99263B9B7F2 Q28554250-A055D580-6647-490F-849A-4B291400E6AA Q31150044-82396BFE-90BA-4354-9ED3-19C989D1C767 Q33775397-29552520-C72F-4862-BEB3-532C7D0E3BD0 Q33909980-F7DE3F62-21FD-486D-A190-8FFB9C43B49A Q33909996-E503BE45-4714-4EEF-835F-A7EC8A985869 Q34057466-6B7E3133-D97B-4AEB-9AAF-BE2F9D2CF9E7 Q34307589-BFC967C0-8CEA-4A8F-9126-E4E38E659AF5 Q34378368-486C6B32-A178-4FA0-9B1F-318865E0183F Q34571645-73F362A5-B387-42B0-8B1E-2D32B06C3004 Q34756398-B545E1AF-8C97-42EF-8B9D-84427FAD72B6 Q34870233-2F21D609-F703-4D1B-9F0D-BB26C8C64A80 Q34977413-78446A9D-E337-47F8-88A8-B2AD6F6CFCF6 Q35043700-C8C5E48C-4EE2-47FA-95A5-AF4B8E09307F Q35056873-FB9942F7-E162-49DC-8D08-1401F90877B6 Q35065867-103C92E8-2E89-4128-8F90-F5CDDBD6D40D Q35114865-BAF2A4F5-CFCE-4397-8C50-6FC2C2EC3A14 Q35185164-6F947402-67C9-4F63-B596-8CF30FCBAD98 Q35288691-156DE225-F497-4D32-A350-66867BF694C2 Q35364120-A8C8F662-888A-4E9B-9EB8-1ABA74F2114C Q35518558-160B97D8-D7D6-4801-B5C1-37066457FE1A Q35547723-7051AE90-488B-47E7-96A1-4D922EF10CE2 Q35654120-A8CF6905-F5BA-44B6-80E4-431A17FAD4A9 Q35661209-DCCF2EDE-112B-4DE5-83D3-6AAFDE14F400 Q35791633-80F8DD91-7889-488A-82F6-36C41DA44D30 Q35846143-067DE126-2297-4160-A088-7FA69FDF545E Q35878413-143085C1-821F-411A-9FE4-181E8BA80B45 Q35887051-5F3F5B5C-AC22-4368-AD56-FBF0AAFACB12 Q35947529-B2E02153-1DFE-4382-BE5D-2B796F9260B8 Q36079108-16698229-F109-4390-B1C4-A1EFEE0F25E6 Q36125023-BBAFED7D-1BD0-40A3-8D24-B70B5662D637 Q36305444-B7001563-A2E7-4B78-A6F7-33BD40875C60 Q36441423-4114E4DB-0BF4-493D-8CC0-BB06750F7462 Q36558501-B28641D0-28DA-420E-BFDC-991EA8A8824B Q36650954-663A39B4-1127-49A3-B44D-E951E6CDA99B Q36657589-636DC421-69DF-40D0-8D76-9702F4E91C23

P2860

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study

http://www.wikidata.org/entity/Q24633579

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Effect of CYP2B6, ABCB1, and C ...... DS Clinical Trials Group study

@ast

Effect of CYP2B6, ABCB1, and C ...... DS Clinical Trials Group study

@en

Effect of CYP2B6, ABCB1, and C ...... DS Clinical Trials Group study

@nl

type

label

Effect of CYP2B6, ABCB1, and C ...... DS Clinical Trials Group study

@ast

Effect of CYP2B6, ABCB1, and C ...... DS Clinical Trials Group study

@en

Effect of CYP2B6, ABCB1, and C ...... DS Clinical Trials Group study

@nl

prefLabel

Effect of CYP2B6, ABCB1, and C ...... DS Clinical Trials Group study

@ast

Effect of CYP2B6, ABCB1, and C ...... DS Clinical Trials Group study

@en

Effect of CYP2B6, ABCB1, and C ...... DS Clinical Trials Group study

@nl

P1433

Q24633579-0E995904-BE81-4060-A01D-408AF7567485

P1476

Q24633579-9FC36841-B915-4740-A833-F0CF95A5294F

P2093

Q24633579-0B6A31FC-B507-456B-AAFA-2CF26E3991CA

Q24633579-1EB56B15-280A-4061-8F6B-DF1D3E6BF383

Q24633579-3773FA6E-2F71-4BA7-9C76-3FAD9456CC95

Q24633579-510814C4-57B5-4E82-9451-CCB66DFB8211

Q24633579-7C0DCCDE-F649-45E8-AA32-D061A4D2A53C

Q24633579-94056350-73F5-44F2-A75E-216523768D68

Q24633579-97C83FD2-F78D-439A-B24F-7C27B62F1DEE

Q24633579-C532E636-4B82-48C6-89A5-0A92A69BE050

Q24633579-C595929E-1D8F-4BF8-99F3-2806D0CF6756

Q24633579-E0C4D7A8-4B32-42B9-8904-5CCD0E6C0F33

P2860

Q24633579-1290B55E-1D5D-4BD0-83CE-BA69CEBF7FD8

Q24633579-34D2E1E6-01DD-4687-96F8-3CE2ABAD5C9C

Q24633579-3A6BF661-FCC6-4E5C-92C2-E2C5D3688956

Q24633579-5A71E9E4-42E1-4E89-8FC2-CA6024CFEB52

Q24633579-67533BEA-6F71-4D1F-AF97-B48D62937746

Q24633579-68882B40-0767-45DB-B122-E77360FB8254

Q24633579-69064F8D-80E0-474D-BD6B-F50599E0B7BB

Q24633579-832BE67D-F160-4756-8AF8-E3245264D3CB

Q24633579-890F97D7-19B2-4FBB-9836-11C94F065993

Q24633579-8ED4F59D-DC4C-4051-BA9D-D70D4945C098

P304

Q24633579-8EA3B903-82C1-4E42-B82D-C44F952691B5

P31

Q24633579-AFAB60CD-406B-443A-AEBB-52E3EC797B24

P3181

Q24633579-7189BCD1-61B0-4E1D-9E58-A4569E2DBB5A

P356

Q24633579-248184F7-145B-4301-8061-F679A4FF541C

P407

Q24633579-C9FCB58F-F72C-413B-8E4A-08375FC2A488

P433

Q24633579-1E5E4E7F-8054-45EE-85B3-17DA70052748

P478

Q24633579-B96D1937-5AAC-47E2-8CFA-4237DEFF6AC7

P50

Q24633579-25BE05C6-72FE-4679-BBC7-1703F70CEA60

Q24633579-8D2EAF4D-DF73-4AD7-8A5A-588B096712FC

Q24633579-DE460CF8-AD2D-4C5E-BD08-D96AE9162C2B

Q24633579-E1630E40-6056-41F7-ACAC-3419CC0D42A5

P577

Q24633579-2F8B0B79-FC33-4915-BA4E-DA05CE6BAD25

P5875

Q24633579-C3B0C5C8-E7EB-4827-B2B9-220495861890

P698

Q24633579-B6847C98-30B1-4A57-A384-A768766035A6

P921

Q24633579-28AF479B-7721-48EA-BB36-2D6D421C79E0

Q24633579-AADF35EE-562C-472A-8889-6F17D42986A5

Q24633579-BB5ECFBE-A372-4FB6-AAB5-092E9919E27B

P932

Q24633579-24BDF593-3C5C-4354-BCED-05C994ACA0A6

P3181

P356

P1433

The Journal of Infectious Diseases

P1476

Effect of CYP2B6, ABCB1, and C ...... DS Clinical Trials Group study

@en

P2093

Alison A Motsinger-Reif

http://www.w3.org/2001/XMLSchema#string

David Clifford

http://www.w3.org/2001/XMLSchema#string

David W Haas

http://www.w3.org/2001/XMLSchema#string

Edward P Acosta

http://www.w3.org/2001/XMLSchema#string

Gene D Morse

http://www.w3.org/2001/XMLSchema#string

Gregory K Robbins

http://www.w3.org/2001/XMLSchema#string

Heather J Ribaudo

http://www.w3.org/2001/XMLSchema#string

Huan Liu

http://www.w3.org/2001/XMLSchema#string

Matthias Schwab

http://www.w3.org/2001/XMLSchema#string

Michel Eichelbaum

http://www.w3.org/2001/XMLSchema#string

P2860

MALDI-TOF mass spectrometry for multiplex genotyping of CYP2B6 single-nucleotide polymorphisms.

Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients

Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus.

Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.

P304

717-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3451970

http://www.w3.org/2001/XMLSchema#string

P356

10.1086/655470

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

202

http://www.w3.org/2001/XMLSchema#string

P50

Marylyn D. Ritchie

Elke Schaeffeler

Alison Motsinger-Reif

Ulrich M. Zanger

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45387592

http://www.w3.org/2001/XMLSchema#string

P698

20662624

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

pharmacokinetics

P932

2919241

http://www.w3.org/2001/XMLSchema#string